Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the ...

Boehringer Ingelheim claimed two Phase 3 wins for its PDE4 inhibitor in fibrotic lung diseases, but some Wall Street analysts said the candidate’s “modest” efficacy and limited combination potential ...

Intellia's CRISPR therapy nexiguran ziclumeran maintained reductions in the levels of a misfolded protein in the nerves of ...

Regeneron is acquiring 23andMe through a court-supervised sale, following 23andMe's bankruptcy filing and recent struggles.

Apnimed's oral drug met the efficacy bar in the first of two Phase 3 studies in obstructive sleep apnea, the biotech said ...

Trump signs executive order on drug pricing via 'most favored nation' model, GSK acquires $1.2B MASH program, Bayer cuts 2,000 jobs, and first CRISPR therapy treats infant.

Sarepta Therapeutics is meeting with the FDA in June to discuss expanding the use of its Duchenne muscular dystrophy gene ...

The government 'did not act contrary to the law' by requiring drugmakers to seek approval before implementing proposed new ...

The Trump administration is partnering with Mark Cuban’s compounding business and four other entities to improve the ...

Rocket Pharmaceuticals reports early success in gene therapy trial for heart condition PKP2-ACM, with 3 patients showing ...

American Society of Gene & Cell Therapy meeting sees 10% drop in attendance. Notable absences include FDA officials, David ...

The FDA is prepping to renegotiate its multibillion-dollar, quinquennial user fee agreements with the drug industry later ...